Hepatic Encephalopathy Pipeline Review, H2 2020: Therapeutic Analysis of 12 Companies & 2 Drug Profiles - ResearchAndMarkets.com

DUBLIN--()--The "Hepatic Encephalopathy - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Hepatic Encephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 7, 4 and 2 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

Key Topics Covered:

Introduction

Report Coverage

Hepatic Encephalopathy - Overview

Hepatic Encephalopathy - Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies

Hepatic Encephalopathy - Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Hepatic Encephalopathy - Companies Involved in Therapeutics Development

  • Alfasigma SpA
  • Axcella Health Inc
  • Cosmo Pharmaceuticals NV
  • Gilead Sciences Inc
  • Grifols SA
  • Kaleido Biosciences Inc
  • KannaLife Sciences Inc
  • Mallinckrodt Plc
  • Rebiotix Inc
  • Takeda Pharmaceutical Co Ltd
  • Umecrine Cognition AB
  • Versantis AG

Hepatic Encephalopathy - Drug Profiles

  • albumin (human) - Drug Profile
  • AXA-1665 - Drug Profile

Hepatic Encephalopathy - Dormant Projects

  • Hepatic Encephalopathy - Discontinued Products

Hepatic Encephalopathy - Product Development Milestones

Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ge5ytq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900